Ranjeet Sinha

Ranjeet Sinha has extensive work experience in the field of translational and clinical sciences. Currently, they hold the position of Director of Translational & Clinical Sciences at Aptose Biosciences, Inc. Their previous roles include being a Group Leader at ONK Therapeutics and a Sr. Scientist at NantKwest, where they focused on cell therapy, including the production and engineering of NK cells and CAR-NK cells. Ranjeet also conducted preclinical efficacy studies. Prior to that, Ranjeet worked as a Staff Scientist and Research Associate at The Scripps Research Institute, leading projects in translational vascular medicine and investigating T cell development. Ranjeet also gained experience as a Scientist at Sorrento Therapeutics, Inc., where they worked on cellular therapy projects and viral vector cloning. Earlier in their career, they served as a Senior Research Fellow at the Indian Institute of Technology, Bombay, focusing on cell signaling and lipid kinase research in T cell activation. Overall, Ranjeet Sinha has a strong background in various aspects of translational and cellular medicine.

Ranjeet Sinha completed their education in a chronological order. Ranjeet first attended Birsa Agricultural University in Ranchi from 1999 to 2002, where they received a Master's degree in Biotechnology. Following this, from 2002 to 2008, they enrolled in the Indian Institute of Technology in Bombay, where they obtained a Doctor of Philosophy (PhD) in Molecular Immunology and Cell Signaling.

After completing their doctoral studies, Ranjeet Sinha joined Scripps Research as a Research Associate. Their work at Scripps Research focused on various fields including Immunology, Biochemistry, Cellular and Molecular Biology, and Vascular Biology. The specific end year of their tenure at Scripps Research is not provided.

In addition to their formal education, Ranjeet Sinha obtained a certification in "Counterintuitive Leadership Strategies for a VUCA Environment" from LinkedIn in July 2020.